Concepedia

Publication | Open Access

Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

DOIFull Paper Access

107

Citations

22

References

2022

Year

Andrew X. Zhu, Farshid Dayyani, Chia‐Jui Yen, Zhenggang Ren, Yuxian Bai, Zhiqiang Meng, Hongming Pan, Paul Dillon, Shivani K. Mhatre, Vincent E. Gaillard,
Clinical Cancer Research

Abstract

AFP response at 6 weeks after initiating treatment is a potential surrogate biomarker of prognosis for patients with HCC receiving atezolizumab + bevacizumab. See related commentary by Cappuyns and Llovet, p. 3405.

References

YearCitations

Page 1